RiverPoint Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 22.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,848 shares of the biopharmaceutical company’s stock after acquiring an additional 3,440 shares during the quarter. RiverPoint Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $1,050,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. Tradewinds Capital Management LLC boosted its stake in Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the period. Welch Investments LLC lifted its stake in Bristol-Myers Squibb by 3.9% during the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 79 shares during the last quarter. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 17 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares during the period. Finally, American National Bank increased its holdings in shares of Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 225 shares during the period. 68.93% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.22 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The firm has a market cap of $101.85 billion, a PE ratio of 21.02, a P/E/G ratio of 2.46 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the prior year, the firm posted $0.77 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% compared to the same quarter last year. analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.51%. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
Several research analysts have recently commented on BMY shares. Credit Suisse Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. Piper Jaffray Companies restated a “hold” rating and set a $60.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday. BMO Capital Markets reiterated an “underperform” rating and set a $47.00 target price (down previously from $51.00) on shares of Bristol-Myers Squibb in a report on Wednesday, July 26th. Finally, Leerink Swann reduced their target price on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $64.93.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.